Comparing the Incidence of Gestational Diabetes in mothers supporting by transvaginal progesterone or 17α-Hydroxyprogesterone Caproate with history of Preterm birth

One of the most important cause of perinatal mortality and morbidity of new born infants is preterm birth .Effectiveness of progesterone derivatives is accepted with passed studies .Abnormalities of glucose tolerance test result is observed in pregnant women with supporting by progesterone derivatives ,after treatment with progesterone suppository or 17 alpha-acetoxyprogesterone.Method &material: In this prospective study we entered 140 women with singleton gestations that had a history of previous preterm birth between 28-37 weeks, without prior positive or unknown history of diabetes before pregnancy or gestational diabetes mellitus in past preterm delivery. For all of them , glucose tolerance test with (75 gram )is ordered between 24 and 28 weeks gestation except for some body that predicted to have glucose intolerance, the test was done sooner than others. All the women used progesterone as 200mg progesterone suppository or 250mg 17 alpha-acetoxyprogesterone injection. from 16 -18 weeks until 37weeks or delivery. All of mothers were observed with the impact of progesterone suppository or 250mg 17 alpha-acetoxyprogesterone for the incidence of GDM.Result: Women supporting by17P ( n=90) had a more higher rate of GDM,(n=25,27.7%) than the women using vaginal progesterone (n=50),(n=5,10%),although BMI and maternal age can affect on results.Conclusion: The use of vaginal progesterone does not appear to be related significantly with risk of GDM but 17P maybe increased risk for the appearance of GDM, we recommend that patients treating with 17P be prone to GDM and we should be screen them sooner than others for GDM.

کلیدواژه ها:

vaginal progesterone. 17 alpha-acetoxyprogesterone ، glucose tolerance test